Institutes of Regenerative Medicine

1. Regenerative Medicine: The Next Frontier Institutes of Regenerative Medicine

2. The Celling Technology Vision The Art of Healing, the Science of Regeneration • “Celling Technologies is dedicated to researching and developing therapies and technologies in the emerging field of Regenerative Medicine to redefine the landscape of medicine and evolve the standard of care in the global healthcare marketplace. Celling Technologies is redefining medicine with Autologous Regenerative Therapies in the 21st Century.”

3. Celling Technologies Today • Celling Technologies is currently pursuing product commercialization and clinical trials throughout the globe with autolgous adult stem cells for therapeutic applications. • 1st human spine case in adipose tissue derived stem cells • 1st prospective human spine study with bone marrow stem cells • Over 9,000 cases with bone marrow concentrated stem cells • On-going animal studies with adult stem cells and carriers • International market expansion (Italy, India, France) in 2009 • 20 Regenerative Medicine Institutes of Excellence • On-going research with major academic institutions • 16 patents pending • 4 proprietary technologies internally designed with FDA approval • Cash flow positive with $3 million allocated to research & development

4. The Regenerative Medicine Market Today What is Regenerative Medicine? Innovative medical therapies that enable the body to repair, replace, restore and regenerate damage or disease cells, tissues and organs. What is an Adult Stem Cell? Unspecialized cells that can self-renew indefinitely and differentiate into mature cells with specialized functions. • 40 years of bone marrow procedures to regenerate blood and immune systems • 1992 Stem cells are identified in the human brain • 1998 The first human embryonic stem cells are isolated • Reported cases: spinal cord injury, leukemia, heart muscle, AIDS, MS, diabetes • A decade of scientific data with over 300 firms trying to commercialize • In 2008, 35 million patients available for stem cell therapeutic treatment • Three stem cell markets: allogenic, autologous, cultured • By 2018, the Orthopedic market - $1.5 billion • By 2018, the stem cell therapeutic market - $8 billion

5. The Regenerative Medicine Market: 4 Year Forecast Source: 2009 Stem Cell Summit, Robin Young, CFA

6. The Regenerative Medicine Market: 4 Year Forecast Source: 2009 Stem Cell Summit, Robin Young, CFA

7. The Regenerative Medicine Institute Profile Celling Technologies is building a network of partners who believe Autologous Regenerative Therapies will redefine the future of medicine (ART-21). We are currently identifying 100 sites that will research and develop the therapeutic value of adult stem cells in Regenerative Medicine. • The Regenerative Medicine Institute Profile: • Spine focused with orthopedic specialists • Multi-disciplinary: Orthopedic, Cardiovascular, Trauma , Plastics • Academic institutions • Innovators and early adopters of cutting edge technology • Embraces Regenerative Medicine • Zealots of the Regenerative Medicine market • Research and development focused • Training and educating capabilities

8. The Benefit of Collaborative Partnerships • Celling Technologies is opening the door with partners into the next generation of medicine and those who advance with us will be the first to enjoy the benefits. Technology Partners • Research Collaborations • Clinical Studies • Product Development • Biotech Commercialization • Patient Education • Public Relations • Healthcare Cost Reduction SpineSmith/Celling Surgeons Hospitals Patients

9. The Benefit of Collaborative Partnerships …the Vision for a Collaborative Partnership • To collaborate and share valuable intellectual property and specialized resources to research, develop and commercialize unique products and therapies in the market of regenerative medicine. • Scientific expertise (PhD) • Mechanical engineering expertise (Design and develop) • Technical expertise • Marketing & commercialization expertise • Major university affiliations and alliances • Surgeon partners • Licensed surgical technicians • Registered nurse practitioners

10. The Celling Technologies Team • Scientific Team • Dr. Jim Poser, PhD Executive Vice President of Regenerative Medicine • Dr. Richard Suzuki, PhD Director or Biomaterial Engineering • Dr. Hugo Pedroza, PhD Director of Cell Therapies • Daria Niedre Associate Director of Clinical Studies (Doctoral Candidate) • Megan Cannon Research Assistant (Doctoral Candidate) • Education/ Training Team • Greg Forman Director of Training and Education • Kathryn Erickson Biotechnology Specialist (Master of Science) • Andrea Dunn, RN Clinical Specialist • Marketing & Business Development • Kevin Were Director of Business Development • Jessica Terrazas Marketing Project Manager • Marisa Cantu Marketing Project Manager • Engineering Team • Robert J Jones Executive Vice President of Innovation • Richard Kana Senior Product Engineer • Tim Leak Product Engineer • John Rossman Bio-engineering Specialist

11. Partner Value Propositions • Value Added Branding “The Regenerative Medicine Institute” • Marketing for hospital • Marketing for surgeons • Cutting edge regenerative medicine product offering • Value Added Resources • Scientists – PhD level specialists for research & development • Engineers – Mechanical engineers for product development • Clinical Coordinators – data collection, storage and analysis • Service – surgical specialists licensed and trained • Technology Product Offering • Adipose tissue derived stem cells • Bone Marrow tissue derived stem cells • Cryopreservation capabilities • Cell Analysis – Real time and lab extensive analysis • Financial Impact • Cost effective pricing with capital equipment cost relief • Coding and reimbursement assistance • Preventative Medicine – cash procedures • Cyropreservation • Training & reference center

12. Regenerative Medicine Product Offering • THE CONTINUUM OF CARE • “We are the only company taking a comprehensive approach to integrate stem cells, biologics, implants and conditioning therapies to effectively treat and heal orthopedic conditions.” Device & Biologics Cryopreservation Pre-Surgical Conditioning

13. Regenerative Medicine Product Offering

14. Regenerative Medicine Expansion 2010-2012 Spine Smith Partners Academic Institutes Direct Sales Strategic Partner Distribution Channels Institutes of Regenerative Medicine International Markets Commercialization Pathway Define stem cell therapy or application Set up study protocols Determine pricing Prove efficacy Define reimbursement Technology Point of care bone marrow Point of care adipose Allogenic “off the shelf” Cryopreservation Expansion Sales Channel Expansion Sales through surgeon partners Sales through Regenerative Medicine Institutes Sales through academic institutions Sales through direct sales force Sales through distribution Sales through international channels Spine Lumbar fusion Cervical fusion Trauma Long bone defects Future Applications Spine Disc injection Spinal cord injury Peripheral nerve Orthopedics Osteoprosis Sports Medicine Joint Therapy Meniscus repair OA Injections ACL Revisions Rotator cuff Labrum repair AVN Cardiovascular Trauma Plastic surgery Dental Anti-Inflammatory Diabetes Therapy Nerve Repair Current Applications

15. Regenerative Medicine Expansion 2010 - 2012 Fusion rating *p value for difference between treatments, Kruskai-Wallis one way ANOVA on Ranks • Higher cell concentration insures patient receives adequate cell population. CONCLUSION: BMAC shows equivalent fusion to IGBG

16. Regenerative Medicine Expansion 2010 - 2012 “Celling Technologies is committed to better understanding the therapeutic value of regenerative medicine and will invest our revenues to research and develop adult stem cell applications with predictable, consistent and reliable results.” • Ongoing Studies • Spine: Human clinical with BMAC • Prospective spinal fusion in PLIF • BMP vs BMAC in ALIF • Cervical fusion with cage, cancellous bone and BMAC • Cervical disc injection • International lumbar fusion efficacy study (Italy) • Spine: Human clinical with adipose derived stem cells • Spinal fusion • Disc injection • Facet injection • Spine: Laboratory research and animal studies • Goat model comparing adipose vs BMAC with carrier • Mechanical separation of adipose tissue • Cartilage tissue growth with adult stem cells • Rabbit model with protein induced stem cell disc injection • Vibration therapy response to stem cell therapy • Prospective Studies • Spine: Adipose derived stem cells • Spinal cord injury • Peripheral nerve • Disc degeneration • Osteoporosis • Orthopedics: BMAC and Adipose derived stem cells • Sports Medicine: Rotator cuff, meniscus, labrum • Joints: Revisions, osteoarthritis, AVN • Knee: Reconstruction, cartilage defect, • Tendinitis • Plastic Surgery: Adipose derived stem cells • Clef lip • Breast augmentation • Cardiovascular: Adipose derived stem cells • Lower limb ischemia

17. Regenerative Medicine: The Next Frontier The Art of Healing, the Science of Regeneration • Autologous Regenerative Therapies of the 21st Century